Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA have?
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA has 95 citations in the OpenAlex counts ScholarIQ stores.
When was Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA published?
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA has 2017 year in the ScholarIQ index.
What is the open-access status of Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA?
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA has bronze oa status in the ScholarIQ index.
What is the DOI of Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA?
The DOI for Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA is on the source record.
What is the PMID of Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA?
The PMID for Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA is on the source record.
What is the OpenAlex record for Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA?
The OpenAlex for Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA is on the source record.